デフォルト表紙
市場調査レポート
商品コード
1436555

骨粗鬆症治療薬の世界市場レポート 2024

Osteoporosis Drugs Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
骨粗鬆症治療薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

骨粗鬆症治療薬の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には3.3%の年間複合成長率(CAGR)で142億米ドルに成長すると予想されます。予測される成長は、人口高齢化の継続的な動向、治療選択肢の進歩、男性の骨の健康への関心の高まり、患者教育、世界の保健政策によって促進されます。主な動向には、個別化医療、併用療法の探求、骨折予防の重視、新規薬剤標的の研究開発、および薬剤開発のための共同努力が含まれます。

骨粗鬆症の有病率の増加は、骨粗鬆症治療薬市場の成長を促進すると予想されます。骨粗鬆症は、骨密度および骨質量の低下、または骨の質および構造の変化を特徴とする骨疾患であり、多くの場合、カルシウム摂取量の低下に関連しています。 骨粗鬆症治療薬は、この病気の影響を受ける人の骨密度を増加させ、骨折を予防する上で重要な役割を果たします。たとえば、2022年 5月の時点で、米国に本拠を置くバイオテクノロジー企業アムジェンの統計によると、骨粗鬆症は米国で年間約150万件の骨折を引き起こしており、関連コストは190億米ドルに達していることが明らかになりました。さらに、骨粗鬆症による年間骨折数は、2018年から2040年にかけて190万件から320万件へと68%増加すると予測されています。したがって、骨粗鬆症の有病率の急増は、骨粗鬆症治療薬市場の成長を促進する重要な要因となっています。

高齢化人口の増加は、予見可能な将来において骨粗鬆症治療薬市場の成長の重要な推進力となると予想されます。人口の高齢化とは、主に出生率の低下と平均余命の延長によって影響を受け、人口の年齢中央値が上昇することを指します。骨粗鬆症のリスクは、骨密度の自然な低下により年齢とともに増加することが知られています。高齢者人口の拡大により、骨粗鬆症治療薬の需要が高まっています。たとえば、スイスに拠点を置く政府間機関である世界保健機関のデータによると、2022年には世界の60歳以上の人口が10億人から14億人に増加しました。 2050年の予測では、60歳以上の世界人口は倍増して21億人に達すると予想されています。したがって、高齢化人口の増加は、骨粗鬆症治療薬市場の成長を促進する重要な要因として浮上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界の骨粗鬆症治療薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ビスホスホネート
  • 選択的エストロゲン受容体調整薬(SERM)
  • RANKリガンド阻害剤
  • 世界の骨粗鬆症治療薬市場、投与別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 注射
  • 世界の骨粗鬆症治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 小売薬局
  • 病院薬局
  • オンライン販売
  • 世界の骨粗鬆症治療薬市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 原発性骨粗鬆症
  • 続発性骨粗鬆症

第7章 地域および国の分析

  • 世界の骨粗鬆症治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の骨粗鬆症治療薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 骨粗鬆症治療薬市場の競合情勢
  • 骨粗鬆症治療薬市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann La Roche Ltd.
    • Merck &Co. Inc.
    • Novartis AG
    • Bristol Myers Squibb Company

第31章 その他の主要および革新的な企業

  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • Amgen Inc.
  • Novo Nordisk A/S
  • Asahi Kasei Pharma Corporation
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV
  • Daiichi Sankyo Company Limited
  • Union Chimique Belge
  • Sun Pharmaceutical Industries Ltd.
  • Ipsen
  • Kyowa Kirin Co. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r15889

Osteoporosis drugs are medications designed to increase bone mineral density, reducing the risk of fractures. They are used both in the treatment and prevention of fractures, aiming to strengthen bones and prevent bone loss associated with osteoporosis.

The primary categories of osteoporosis drugs comprise bisphosphonates, selective estrogen receptor modulators (SERMS), and rank ligand inhibitors. Bisphosphonates are a class of medications aimed at addressing bone conditions such as osteopenia or osteoporosis, both characterized by fragile or thin bones susceptible to fractures. These drugs are available in oral and intravenous forms, distributed through diverse channels such as retail pharmacies, hospital dispensaries, and online sales platforms. They find application in treating both primary and secondary osteoporosis.

The osteoporosis drugs market research report is one of a series of new reports from The Business Research Company that provides osteoporosis drugs market statistics, including osteoporosis drugs industry global market size, regional shares, competitors with a osteoporosis drugs market share, detailed osteoporosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis drugs industry. This osteoporosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12 billion in 2023 to $12.48 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. The growth observed in the historical period can be attributed to an aging population, heightened awareness and diagnosis, lifestyle factors, and government initiatives and healthcare policies.

The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The forecasted growth is driven by continuing trends of an aging population, advancements in treatment options, increased focus on men's bone health, patient education, and global health policies. Key trends include personalized medicine, exploration of combination therapies, emphasis on fracture prevention, research and development in novel drug targets, and collaborative efforts for drug development.

The increasing prevalence of osteoporosis is anticipated to drive the growth of the osteoporosis drug market. Osteoporosis, a bone disease characterized by a decline in bone mineral density and mass or changes in bone quality and structure, is often associated with low calcium intake. Osteoporosis drugs play a crucial role in increasing bone mineral density and preventing fractures in individuals affected by the condition. For example, as of May 2022, statistics from Amgen, a US-based biotechnology company, revealed that osteoporosis causes approximately 1.5 million fractures in the United States annually, resulting in associated costs amounting to $19 billion. Furthermore, the annual number of fractures caused by osteoporosis is projected to increase by 68% from 2018 to 2040, rising from 1.9 million to 3.2 million. Consequently, the surging prevalence of osteoporosis stands as a key factor driving the growth of the osteoporosis drug market.

The rising aging population is anticipated to be a significant driver for the growth of the osteoporosis drug market in the foreseeable future. The aging population refers to an increase in the median age of a population, primarily influenced by declining fertility rates and prolonged life expectancy. Osteoporosis risk is known to escalate with age due to the natural decline in bone density. The expanding demographic of elderly individuals contributes to a growing demand for osteoporosis medications. For example, in 2022, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that the global population aged 60 years and over increased from 1 billion to 1.4 billion. Projections for 2050 anticipate a doubling of the world's population of individuals aged 60 years and older to reach 2.1 billion. Hence, the increasing aging population emerges as a key factor driving the growth of the osteoporosis drug market.

Key players in the osteoporosis drugs industry are driving forward with innovative approaches to address this market. An example of this progress is seen in Apotex Inc., a Canadian pharmaceutical giant, which introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This pre-filled pen, containing 250 mcg/mL, facilitates 28 daily doses of 20 mcg each, specifically designed for single-patient usage. This offering aims to provide affordable access to much-needed treatment for patients dealing with osteoporosis.

Major players in the osteoporosis drug market are strategically leveraging partnerships to ensure dependable services for their clientele. A case in point is the December 2022 collaboration between Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, and Towa Pharmaceutical Co. Ltd., a Japan-based manufacturer specializing in generic drug development. This alliance facilitated the introduction of Edirol Tablet for osteoporosis treatment. Chugai's production of Edirol tablets, supplied to Towa, showcases this active vitamin D3 derivative's efficacy in enhancing calcium and bone metabolism. This joint effort significantly contributes to diversifying treatment options available in the osteoporosis drug market, addressing the needs of individuals dealing with this condition.

In August 2021, Nestle Health Science, a Switzerland-based provider of nutrition solutions, diagnostics, devices, and drugs, successfully acquired the core brands of Bountiful Company for an undisclosed amount. This strategic acquisition is aimed at enhancing Nestle Health Science's portfolio with trusted products and methodologies, further advancing its mission to improve the health of clients globally. Bountiful Company, based in the United States, is recognized for its joint care supplement brand.

Major companies operating in the osteoporosis drugs market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Union Chimique Belge, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Enzene Biosciences Ltd., Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Ligand Pharmaceuticals Incorporated, Theramex, Radius Health Inc., Actavis PLC, Strides Pharma Science Limited, Apotex Inc.

North America was the largest region in the osteoporosis market in 2023. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis drugs market consists of sales of antiresorptive drugs and anabolic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteoporosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors
  • 2) By Administration: Oral; Injectable
  • 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
  • 4) By Application: Primary Osteoporosis; Secondary Osteoporosis
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol Myers Squibb Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osteoporosis Drugs Market Characteristics

3. Osteoporosis Drugs Market Trends And Strategies

4. Osteoporosis Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Osteoporosis Drugs Market Size and Growth

  • 5.1. Global Osteoporosis Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Osteoporosis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Osteoporosis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Osteoporosis Drugs Market Segmentation

  • 6.1. Global Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bisphosphonates
  • Selective Estrogen Receptor Modulators (SERMs)
  • RANK Ligand Inhibitors
  • 6.2. Global Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectable
  • 6.3. Global Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Sales
  • 6.4. Global Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Primary Osteoporosis
  • Secondary Osteoporosis

7. Osteoporosis Drugs Market Regional And Country Analysis

  • 7.1. Global Osteoporosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Osteoporosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Osteoporosis Drugs Market

  • 8.1. Asia-Pacific Osteoporosis Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Osteoporosis Drugs Market

  • 9.1. China Osteoporosis Drugs Market Overview
  • 9.2. China Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Osteoporosis Drugs Market

  • 10.1. India Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Osteoporosis Drugs Market

  • 11.1. Japan Osteoporosis Drugs Market Overview
  • 11.2. Japan Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Osteoporosis Drugs Market

  • 12.1. Australia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Osteoporosis Drugs Market

  • 13.1. Indonesia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Osteoporosis Drugs Market

  • 14.1. South Korea Osteoporosis Drugs Market Overview
  • 14.2. South Korea Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Osteoporosis Drugs Market

  • 15.1. Western Europe Osteoporosis Drugs Market Overview
  • 15.2. Western Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Osteoporosis Drugs Market

  • 16.1. UK Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Osteoporosis Drugs Market

  • 17.1. Germany Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Osteoporosis Drugs Market

  • 18.1. France Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Osteoporosis Drugs Market

  • 19.1. Italy Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Osteoporosis Drugs Market

  • 20.1. Spain Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Osteoporosis Drugs Market

  • 21.1. Eastern Europe Osteoporosis Drugs Market Overview
  • 21.2. Eastern Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Osteoporosis Drugs Market

  • 22.1. Russia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Osteoporosis Drugs Market

  • 23.1. North America Osteoporosis Drugs Market Overview
  • 23.2. North America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Osteoporosis Drugs Market

  • 24.1. USA Osteoporosis Drugs Market Overview
  • 24.2. USA Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Osteoporosis Drugs Market

  • 25.1. Canada Osteoporosis Drugs Market Overview
  • 25.2. Canada Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Osteoporosis Drugs Market

  • 26.1. South America Osteoporosis Drugs Market Overview
  • 26.2. South America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Osteoporosis Drugs Market

  • 27.1. Brazil Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Osteoporosis Drugs Market

  • 28.1. Middle East Osteoporosis Drugs Market Overview
  • 28.2. Middle East Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Osteoporosis Drugs Market

  • 29.1. Africa Osteoporosis Drugs Market Overview
  • 29.2. Africa Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Osteoporosis Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Osteoporosis Drugs Market Competitive Landscape
  • 30.2. Osteoporosis Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bristol Myers Squibb Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Osteoporosis Drugs Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline PLC
  • 31.2. Eli Lilly and Company
  • 31.3. Amgen Inc.
  • 31.4. Novo Nordisk A/S
  • 31.5. Asahi Kasei Pharma Corporation
  • 31.6. Viatris Inc.
  • 31.7. Teva Pharmaceutical Industries Ltd
  • 31.8. Mylan N.V.
  • 31.9. Daiichi Sankyo Company Limited
  • 31.10. Union Chimique Belge
  • 31.11. Sun Pharmaceutical Industries Ltd.
  • 31.12. Ipsen
  • 31.13. Kyowa Kirin Co. Ltd.
  • 31.14. Dr. Reddy's Laboratories Ltd.
  • 31.15. Cipla Limited

32. Global Osteoporosis Drugs Market Competitive Benchmarking

33. Global Osteoporosis Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Osteoporosis Drugs Market

35. Osteoporosis Drugs Market Future Outlook and Potential Analysis

  • 35.1 Osteoporosis Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Osteoporosis Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Osteoporosis Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer